Evidence map›Paper›PMID 39003442›Full record

Observational studyBMC cancer2024

Association of low adherence to weekly cisplatin with outcomes in patients with head and neck squamous cell carcinoma: a retrospective cohort study.

Jas Virk, Jasmin Gill, Fatemeh Fekrmandi, Austin Iovoli, Mark Farrugia, Ayham Al-Afif, Kimberly Wooten, Vishal Gupta, Ryan McSpadden, Moni A Kuriakose and 4 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jas VirkJacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, 955 Main Street, Buffalo, NY, 14203, USA.
Jasmin GillUniversity at Buffalo, The State University of New York, 12 Capen Hall, Buffalo, NY, 14260, USA.
Fatemeh FekrmandiDepartment of Radiation Medicine, Roswell Park Comprehensive Cancer Center, 665 Elm and Carlton Streets, Buffalo, NY, 14203, USA.
Austin IovoliDepartment of Radiation Medicine, Roswell Park Comprehensive Cancer Center, 665 Elm and Carlton Streets, Buffalo, NY, 14203, USA.
Mark FarrugiaDepartment of Radiation Medicine, Roswell Park Comprehensive Cancer Center, 665 Elm and Carlton Streets, Buffalo, NY, 14203, USA.
Ayham Al-AfifDepartment of Head and Neck Surgery, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, 14203, USA.
Kimberly WootenDepartment of Head and Neck Surgery, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, 14203, USA.
Vishal GuptaDepartment of Head and Neck Surgery, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, 14203, USA.
Ryan McSpaddenDepartment of Head and Neck Surgery, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, 14203, USA.
Moni A KuriakoseDepartment of Head and Neck Surgery, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, 14203, USA.
Michael R MarkiewiczDepartment of Oral and Maxillofacial Surgery, School of Dental Medicine, University at Buffalo, The State University of New York, 3435 Main Street, Buffalo, NY, 14214, USA.
Wesley L HicksDepartment of Head and Neck Surgery, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, 14203, USA.
Sung Jun MaDepartment of Radiation Medicine, Roswell Park Comprehensive Cancer Center, 665 Elm and Carlton Streets, Buffalo, NY, 14203, USA. SungJun.Ma@osumc.edu.
Anurag K SinghDepartment of Radiation Medicine, Roswell Park Comprehensive Cancer Center, 665 Elm and Carlton Streets, Buffalo, NY, 14203, USA. Anurag.Singh@RoswellPark.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe National Comprehensive Cancer Network (NCCN) guideline recommends consideration of weekly cisplatin as an alternative option for patients with head and neck cancer undergoing definitive chemoradiation. However, in a recent phase III trial (ConCERT), 20% of patients treated with weekly cisplatin could not receive a total of 200 mg/m

methodsOur institutional database was queried for patients with non-metastatic head and neck cancer who underwent definitive chemoradiation with weekly cisplatin (40 mg/m

resultsAmong 119 patients who met our criteria, 51 patients (42.9%) had low adherence to weekly cisplatin. Median follow up was 19.8 months (interquartile range 8.8-65.6). Low adherence to weekly cisplatin was associated with worse overall survival (adjusted hazards ratio [aHR] 2.94, 95% confidence interval [CI] 1.58-5.47, p < 0.001) and progression-free survival (aHR 2.32, 95% CI 1.29-4.17, p = 0.005). It was also associated with worse distant failure (aHR 4.55, 95% CI 1.19-17.3, p = 0.03), but not locoregional failure (aHR 1.61, 95% CI 0.46-5.58, p = 0.46). KPS < 90 was the only variable associated with low adherence to weekly cisplatin (adjusted odds ratio [aOR] 2.67, 95% CI 1.10-6.65, p = 0.03).

conclusionOur study suggested that over 40% of patients underwent fewer than 5 weekly cisplatin cycles and that low adherence to weekly cisplatin was an independent, adverse prognostic factor for worse survival and distant failure outcomes. Those with reduced adherence to weekly cisplatin were more likely to have poor performance status. Further studies are warranted to improve the adherence to chemotherapy and outcomes.

Indexed as

ChemoradiotherapyCisplatinHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckAdultAgedAntineoplastic AgentsDrug Administration ScheduleDrug MonitoringFemaleHumansKaplan-Meier EstimateMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntineoplastic AgentsCisplatinAdherenceChemoRTComplianceConcurrent chemotherapyHead and neck cancerWeekly cisplatin

Identifiers

PMID39003442
PMCPMC11245783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.